LBH589/lenalidomide regulates, IRF4 and promotes apoptosis of multiple myeloma cells
10.3969/j.issn.1671-8348.2018.11.006
- VernacularTitle:LBH589/来那度胺调控多发性骨髓瘤细胞中IRF4并促进凋亡反应的研究
- Author:
Sishi TANG
1
;
Dan MA
;
Bingqing CHENG
;
Ling Kun YU
;
Jishi WANG
;
Yan PENG
Author Information
1. 贵州医科大学
- Keywords:
histone deacetylase inhibitor;
lenlidomide;
multiple myeloma;
IRF4
- From:
Chongqing Medicine
2018;47(11):1452-1456
- CountryChina
- Language:Chinese
-
Abstract:
Objective We aimed to investigate the expression of IRF4 and apoptosis of the histone deacetylase inhibitor LBH589 against MM cells in vitro,and study the mechanism of apoptosis when LBH589 alone or/and combined with lenalidomide in RPMI8226 cell so as to provide a new strategy for the treatment of multiple myeloma.Methods The cell viability on the growth of RPMI8226 cell were assessed by CCK8 assay.Apoptosis were measured by flow cytometry,The Grandpad software analyzes the statistical significance and evaluates the synergistic effect of the drug.The expression level of the related transcription factor and apoptotic gene protein were determined by western blot.The cell viability on the growth of RPMI8226-R cell were assessed by CCK8.Results LBH589 combined with lenalidomide have significant effect on inhibit cell proliferation and induce apoptosis in a dose-dependent manner.Apoptosis induced by LBH589/lenalidomide alone or combination was shown to involved PARP activation,decreased Bcl-2 and Bcl-xl expression.significantly down regulated transcriptional related factors of IRF4 and c-MYC expression compared with either agent alone.Conclusion LBH589 and lenalidomide alone or combination decrease the expression of transcription factor IRF4 and c-MYC,and have a significant synergistic effect,and highly expression of IRF in RPMI8226-R reduce proliferation inhibition.
